{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-021643","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.510972+00:00","generated_at":"2026-06-05T09:12:28.533072+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pyxis Oncology raises ~$50M in private placement of shares and pre-funded warrants","bullets":["Gross proceeds of ~$50M from 8.85M shares at $4.78 and pre-funded warrants for 1.61M shares at $4.779.","Participants include Deep Track Capital, Ridgeback Capital, Blue Owl Healthcare, Laurion Capital, and StemPoint Capital.","Proceeds to fund development of lead ADC candidate PYX-201 for solid tumors and for working capital.","Private placement expected to close on or about Feb 29, 2024; registration statement to be filed by Mar 27, 2024.","Leerink Partners serving as lead placement agent; LifeSci Capital as co-placement agent."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-021643","json":"https://secwatch.observer/filing/0000950170-24-021643.json","markdown":"https://secwatch.observer/filing/0000950170-24-021643.md","text":"https://secwatch.observer/filing/0000950170-24-021643.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000095017024021643/0000950170-24-021643-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000095017024021643/pyxs-20240226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T09:12:28.533072+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"554392dcff6f4d327fd63e481c70e9d373553ee4","claim":"Pyxis Oncology, Inc. entered into Registration Rights Agreement with the Purchasers (effective 2024-02-26).","evidence_excerpt":"On February 26, 2024, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Purchasers, pursuant to which the Company agreed to register for resale the Shares and the Pre-Funded Warrant Shares held by the Purchasers (the “Registrable Securities”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782223/000095017024021643/0000950170-24-021643-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"the Purchasers"},{"label":"Effective","value":"2024-02-26"}],"fact_type":"material_agreement"},{"claim_id":"b4c448e12aa39ca35dced94aa3ee456b8efe3a3e","claim":"Pyxis Oncology, Inc. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at approximately $50 million (effective 2024-02-26).","evidence_excerpt":"On February 26, 2024, Pyxis Oncology, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) for a private placement (the “Private Placement”) with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782223/000095017024021643/0000950170-24-021643-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional and accredited investors"},{"label":"Value","value":"approximately $50 million"},{"label":"Effective","value":"2024-02-26"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}